MRK News and Press, Merck & Company Inc. From 06/17/24

KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status Approval marks the third FDA-approved indication for KEYTRUDA in endometrial ...

2024-06-17 15:37:41 ET Summary For dividend growth investing, is growth more important than valuation? 49 stocks are valued based on Historical and Future Fair Valuations as well as analyst estimates. 49 stocks are further evaluated based on past dividend growth and future pro...

2024-06-17 13:47:48 ET More on Merck Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying Merck shares traded in the green for seven straight days AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes Merck & Co., ...

NORTHAMPTON, MA / ACCESSWIRE / June 12, 2024 / Merck & Co., Inc. Strong career paths and cutting-edge science draw more women scientists - like chemists and engineers - to the company's small molecule process R&D team Women scientists have historically been underrepresented in the f...

2024-06-12 03:27:58 ET Summary Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the primary revenue driver today, has shown promising r...

2024-06-11 13:19:13 ET Summary Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size ...

2024-06-11 12:34:07 ET Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024, 10:00 AM ET Company Participants Robert Davis - Chairman, President and Chief Executive Officer Dean Li - Executive Vice President and Presid...

2024-06-11 12:08:45 ET Summary Corcept Therapeutics Incorporated share prices were initially suppressed after a court ruling that Teva's generic version of Korlym would not infringe on its patents. However, the company is preparing an NDA for Korlym's successor, which could be app...

2024-06-11 08:37:32 ET Summary Affimed's 06/01/24 update on AFM24 means the company has a second viable commercial asset.  This is why the stock popped after ASCO. Acimtamig's update is due before the end of this month.  If it is positive, the stock should run again for ...

2024-06-10 16:18:31 ET Merck & Co ( NYSE: MRK ) shares traded in the green on Monday, making it the seventh straight day of gains. The stock closed up 0.63% at $131.49.... Read the full article on Seeking Alpha For further details see: Merck shares traded in the ...